ING Group
CAI icon

ING Group’s Caris Life Sciences CAI Stock Holding History

ING Group’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$15.2M Buy
+496,100
New +$11.1M 0.09% 191

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $144B AUM 22.91% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
SEI Investments
SEI Investments Oaks, Pennsylvania $113B AUM 26.61% 1-Year Est. Return
Zevenbergen Capital Investments
Zevenbergen Capital Investments Edmonds, Washington $4.37B AUM 52.9% 1-Year Est. Return

ING Group's CAI Position: Q3 2026 in Review

ING Group opened a new position in Caris Life Sciences (CAI) in Q3 2026: 496,100 shares worth $15.2M. The stake represents 0.09% of the portfolio and ranks #191 among its holdings.

165 funds tracked by Wall St. Rank hold CAI as of Q3 2026.

  • ING Group held 496,100 shares of Caris Life Sciences worth $15.2M as of Q3 2026.
  • Caris Life Sciences was a new ING Group position in Q3 2026.
  • Caris Life Sciences made up 0.09% of ING Group's portfolio in Q3 2026, its #191 holding.
  • 165 funds tracked by Wall St. Rank held Caris Life Sciences as of Q3 2026.

Based on ING Group's 13F filing for Q3 2026, filed 10 Nov 2026.